Cryoport, Inc. CYRX
We take great care to ensure that the data presented and summarized in this overview for Cryoport, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CYRX
View all-
Cadian Capital Management, LP New York, NY4.98MShares$33.4 Million1.3% of portfolio
-
Morgan Stanley New York, NY4.63MShares$31.1 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD4.05MShares$27.2 Million0.76% of portfolio
-
Black Rock Inc. New York, NY3.42MShares$22.9 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.36MShares$22.6 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.75MShares$18.4 Million0.0% of portfolio
-
Fred Alger Management, LLC New York, NY2.53MShares$17 Million0.09% of portfolio
-
Thematics Asset Management Paris, I01.7MShares$11.4 Million0.53% of portfolio
-
Deutsche Bank Ag\ Frankfurt Am Main, 2M1.39MShares$9.34 Million0.0% of portfolio
-
New York State Common Retirement Fund1.15MShares$7.69 Million0.01% of portfolio
Latest Institutional Activity in CYRX
Top Purchases
Top Sells
About CYRX
Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle. It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems. In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services. It serves biopharma/pharma, animal health, and human reproductive medicine markets. The company was founded in 1999 and is headquartered in Brentwood, Tennessee.
Insider Transactions at CYRX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jul 08
2025
|
Jerrell Shelton President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+2.53%
|
$125,000
$5.0 P/Share
|
Jun 25
2025
|
Jerrell Shelton President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+2.6%
|
$125,000
$5.0 P/Share
|
Jun 24
2025
|
Ramkumar Mandalam Director |
SELL
Open market or private sale
|
Direct |
13,321
-15.42%
|
$93,247
$7.01 P/Share
|
Jun 24
2025
|
Ramkumar Mandalam Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+18.8%
|
$60,000
$3.07 P/Share
|
Jun 24
2025
|
Jerrell Shelton President, CEO |
SELL
Open market or private sale
|
Direct |
16,344
-1.76%
|
$114,408
$7.06 P/Share
|
Jun 24
2025
|
Jerrell Shelton President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
16,344
+1.73%
|
$81,720
$5.0 P/Share
|
Jun 20
2025
|
Jerrell Shelton President, CEO |
SELL
Open market or private sale
|
Direct |
69,135
-7.04%
|
$414,810
$6.47 P/Share
|
Jun 20
2025
|
Jerrell Shelton President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
69,135
+6.58%
|
$345,675
$5.0 P/Share
|
Jun 18
2025
|
Jerrell Shelton President, CEO |
SELL
Open market or private sale
|
Direct |
119,281
-11.56%
|
$715,686
$6.81 P/Share
|
Jun 18
2025
|
Jerrell Shelton President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
119,281
+10.36%
|
$596,405
$5.0 P/Share
|
Jun 17
2025
|
Jerrell Shelton President, CEO |
SELL
Open market or private sale
|
Direct |
151,304
-14.22%
|
$907,824
$6.81 P/Share
|
Jun 17
2025
|
Jerrell Shelton President, CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
201,304
+8.82%
|
$1,006,520
$5.0 P/Share
|
Jun 13
2025
|
Ramkumar Mandalam Director |
SELL
Open market or private sale
|
Direct |
624
-0.93%
|
$3,744
$6.8 P/Share
|
Jun 12
2025
|
Ramkumar Mandalam Director |
SELL
Open market or private sale
|
Direct |
1,895
-2.75%
|
$13,265
$7.01 P/Share
|
Jun 11
2025
|
Ramkumar Mandalam Director |
SELL
Open market or private sale
|
Direct |
8,193
-10.63%
|
$57,351
$7.06 P/Share
|
Jun 10
2025
|
Edward J Zecchini Chief Digital and Tech Officer |
SELL
Open market or private sale
|
Direct |
51,500
-36.29%
|
$309,000
$6.84 P/Share
|
Jun 10
2025
|
Edward J Zecchini Chief Digital and Tech Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
75,000
+34.58%
|
$225,000
$3.07 P/Share
|
Jun 09
2025
|
Ramkumar Mandalam Director |
SELL
Open market or private sale
|
Direct |
5,622
-6.8%
|
$39,354
$7.06 P/Share
|
Jun 06
2025
|
Ramkumar Mandalam Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,214
+21.92%
|
-
|
Jun 06
2025
|
Daniel M Hancock Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,214
+28.34%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 150K shares |
---|---|
Exercise of conversion of derivative security | 950K shares |
Open market or private sale | 711K shares |
---|---|
Exercise of conversion of derivative security | 50K shares |